eLearningClasses.com

Medicrea Reports First Half 2019 Financial Results

Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on globalbankingandfinance.com is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies Sponsored Posts etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at globalbankingandfinance.com with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. Globalbankingandfinance.com also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites. Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. A very few articles on our website are sponsored posts or paid advertorials. These are marked as sponsored posts at the bottom of each post. For avoidance of any doubts and to make it easier for you to differentiate sponsored or non-sponsored articles or links, you may consider all articles on our site or all links to external websites as sponsored . Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.

The Medicrea Group (Euronext Growth Paris: FR0004178572-ALMED ; OTCQX Best Market “MRNTF), pioneering the digital transformation of spinal surgery through artificial Intelligence, predictive modeling and patient specific implants with its UNiD„¢ ASI (Adaptive Spine Intelligence) proprietary software platform, services and technologies, reports its unaudited results for the first half of 2019, as approved by the Board of Directors on September 16, 2019.

‚¬million

H1 2019

H1 2018 (2)

Restated

Sales

Gross margin – % of sales

EBITDA (1)

Operating income

Other operating income and expense

Share-based payments

Cost of net financial debt

Income before taxes

Net Income

16.1

77%

0.6

(3.4)

(0.5)

(1.0)

(2.0)

(6.9)

(7.0)

16.9

68%

(0.5)

(4.5)

(0.4)

(0.4)

(1.4)

(6.7)

(6.6)

(1) : Operating income before interest depreciation and amortization (2) : After IFRS 16 “Leases” adjustments applicable since January 1, 2019

Sales for the first half of 2019 amounted to 16.1 million euros, up 10% (+6% at constant exchange rates) compared to 2018 on a pro-forma basis, mainly related to the development of the business in the United States. As previously mentioned, reported revenue was down 5% following the discontinuation of non-strategic activities since the beginning of 2019, which had generated ‚¬2.3 million in sales until 30 June 2018.

The improvement in gross margin observed over the past year is strengthening, reaching 77% in the first half of 2019, a significant increase of +9 points compared to the same period last year. This performance is based on two major controlled and sustainable elements: a favorable sales mix with the growing contribution of the United States, as well as better industrial efficiency and less subcontracting, which should make it possible to maintain a high margin level over the coming quarters, approaching the normative threshold of 80%.

Operating expenses amounted to ‚¬ 15.8 million in the first half of 2019, down ‚¬ 0.9 million compared to the first half of 2018 after neutralization of currency effects, thanks to a tight control of marketing and administrative expenses. Investments in Research and Development remained stable. Operating income before interest depreciation and amortization (EBITDA), after taking into account IFRS 16 changes, is positive at ‚¬ 0.6 million.

Given these elements, operating income improved by 1.1 million euros at -3.4 million euros.

Share-based payments with no cash impact arising from free shares and stock options granted in the last quarter of 2018 amounted to 1 million euro. The cost of net financial debt increased by ‚¬ 0.9 million as a result of interest expense on the $ 30 million bond issued in December 2018 and interest expense of ‚¬ 0.2 million due to IFRS 16 accounting changes.

Outlook

Commercial activity in the third quarter is strong despite the seasonality effect of this period. Strong sales in the United States and continued growth in other markets should translate into one of the best quarterly performances in terms of revenue.

This positive trend particularly relates to the UNiD ASI„¢ strategic activity of preoperative surgical planning and patient-specific implant design: since the beginning of the year, 1,160 personalized surgeries have been performed at the end of August 2019, an increase of +49% compared to the same period in 2018 with a record number of 184 surgeries performed in August, also following a very good month in July. In the United States, UNiD„¢ surgeries now account for 66% of the subsidiary’s revenue.

« We are witnessing a rapid evolution of the spine market, which will change dramatically with the development of artificial intelligence and the digitalization of services in operating rooms. In this context, the control and analysis of pre-, intra- and post-operative data to achieve better clinical outcomes and safer and more comfortable surgery for surgeons and patients become a key competitive edge. With the milestone of 5,000 cumulative personalized UNiD„¢ surgeries to be achieved in 2019, close collaboration with the world’s most renowned surgeons, very broad patent protection over intellectual property and the regular introduction of new innovations (selection of screws before surgery, predictive models, etc.), Medicrea has gained a significant lead over its competitors and has unique assets to establish its position as a leader and pioneer in personalized spinal surgery. » commented Denys Sournac, President and CEO of Medicrea.

Next publication: 2019 Third Quarter sales: October 10, 2019, after market.

About Medicrea (www.medicrea.com)

Through the lens of predictive medicine, Medicrea leverages its proprietary software analysis tools with big data and machine learning technologies supported by an expansive collection of clinical and scientific data. The Company is well-placed to streamline the efficiency of spinal care, reduce procedural complications and limit time spent in the operating room.

Operating in a $10 billion marketplace, Medicrea is a Small and Medium sized Enterprise (SME) with 180 employees worldwide, which includes 40 who are based in the U.S. The Company has an ultra-modern manufacturing facility in Lyon, France housing the development and production of 3D- printed titanium patient-specific implants.

For further information, please visit: Medicrea.com.

Connect with Medicrea

FACEBOOK | INSTAGRAM | TWITTER | WEBSITE | YOUTUBE

Medicrea is listed on EURONEXT Growth Paris ISIN: FR 0004178572 Ticker: ALMED LEI: 969500BR1CPTYMTJBA37

Medicrea is traded on OTCQX Best Market Ticker: MRNTF

Medicrea

Denys SOURNAC

Founder, Chairman and CEO

[email protected]

Fabrice KILFIGER

Chief Financial Officer

[email protected]

Tel: +33 (0)4 72 01 87 87